Skip to main content

José Antonio Arranz Amo

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

José Antonio Arranz Amo

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Desarrollo de una nueva terapia de reemplazo enzimático basada en nanotecnología para la enfermedad de Parkinson: restablecimiento de la actividad glucocerebrosidasa lisosomal mediante nanoconjugación enzima-polímero de GBA (NANO-ERT).

IP: Marta Martínez Vicente
Collaborators: Eddie Pradas Gracia, David Moreno Martinez, Jordi Riera Heredia, José Antonio Arranz Amo, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres
Funding agency: Fundación Banco Bilbao Vizcaya Argentaria
Funding: 124047.74
Reference: BBVA/INVESTIGACIO/MARTINEZ
Duration: 01/05/2020 - 30/07/2023

Enfermedades minoritarias causantes de degeneración de ganglios basales en pedriatría: implemementación combinada del análisis genómico y de biomarcadores.

IP: Belen Perez Dueñas
Collaborators: José Antonio Arranz Amo, Josefa Élida Vázquez Méndez, Alfons Macaya Ruíz, Anna Marcé Grau, Clara Carnicer Cáceres, Mireia del Toro Riera, Ana Felipe Rucián
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/01319
Duration: 01/01/2019 - 31/12/2022

Apolipoproteína AIb como biomarcador y diana terapéutica de la glomeruloesclerosis segmentaria y focal idiopática (GESF)

IP: Joan López Hellin
Collaborators: José Antonio Arranz Amo, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Instituto de Salud Carlos III
Funding: 88935
Reference: PI14/00275
Duration: 01/01/2015 - 30/06/2018

Neurodegeneración en la cirrosis hepática: relación con el metabolismo nitrogenado y la inflamación

IP: -
Collaborators: José Antonio Arranz Amo, Xavier Nuvials Casals, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 215544.56
Reference: PI11/00954
Duration: 01/01/2012 - 31/03/2016

Related news

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

Related professionals

Cristina Bernadó Morales

Cristina Bernadó Morales

Predoctoral researcher
Donation and transplantation of organs, tissues and cells
Read more
Joaquim Mateo Valderrama

Joaquim Mateo Valderrama

Main researcher
Read more
Luis silvestre Chiscano Camon

Luis silvestre Chiscano Camon

Junior researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Sonia  Monreal  Clua

Sonia Monreal Clua

Predoctoral researcher
Biomedical Research in Gynaecology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.